Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17138221 | Micro-fog anti pathogenic composition and method of preparation | December 2020 | December 2022 | Abandon | 24 | 2 | 1 | Yes | No |
| 17135152 | FUNCTIONAL TEA CONTAINING BENEFICIAL INGREDIENTS FOR THE HUMAN BODY | December 2020 | December 2022 | Abandon | 24 | 1 | 1 | No | No |
| 17255604 | PHARMACEUTICAL COMPOSITION FOR ALLEVIATING EYE FATIGUE, CONTAINING, AS ACTIVE INGREDIENTS, LUTEOLIN-7-O-DIGLUCURONIDE AND APIGENIN-7-O-DIGLUCURONIDE ISOLATED FROM PERILLA FRUTESCENS (L.) BRITTON VAR. ACUTA (THUNB.) KUDO LEAF EXTRACT | December 2020 | December 2022 | Abandon | 24 | 1 | 0 | Yes | No |
| 17123929 | PROCESS FOR PRODUCING AN EXTRACT CONTAINING TETRAHYDROCANNABINOL AND CANNABIDIOL FROM CANNABIS PLANT MATERIAL, AND CANNABIS EXTRACTS | December 2020 | December 2021 | Abandon | 11 | 1 | 0 | No | No |
| 16972066 | COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING COMPLICATIONS OF OBESITY | December 2020 | November 2024 | Abandon | 47 | 4 | 1 | Yes | No |
| 17100750 | METHOD FOR ISOLATION OF MAO INHIBITORS FROM TEQUILA OR OTHER DISTILLED AGAVE FERMENTATION PRODUCTS | November 2020 | May 2023 | Abandon | 29 | 2 | 0 | No | No |
| 17055822 | EUTECTIC EXTRACT FORMATION AND PURIFICATION | November 2020 | June 2023 | Allow | 31 | 1 | 1 | No | No |
| 17089989 | METHOD TO PREPARE A THERAPEUTIC BALM | November 2020 | August 2022 | Allow | 21 | 1 | 0 | No | No |
| 17078406 | Botanical Synergistic Activated/Native and Equivalents Thereof | October 2020 | September 2024 | Abandon | 47 | 4 | 0 | No | No |
| 17075868 | COMPOUND ESSENTIAL OIL COMPOSITION AND USE THEREOF FOR IMPROVING COGNITION, SLEEP AND MOOD | October 2020 | October 2022 | Abandon | 23 | 1 | 0 | No | No |
| 17072246 | COMPOSITIONS CONTAINING KRATOM COMPOUNDS | October 2020 | February 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17026801 | Pharmaceutical Composition Based on Plant Raw Materials | September 2020 | June 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 17027006 | PROMOTING SLEEP USING AT1 RECEPTOR BLOCKERS | September 2020 | May 2022 | Allow | 20 | 1 | 0 | No | No |
| 15733622 | Preparation Method of Agrocybe Aegerita Extract and its use in Preparing Medicine for Lowering Uric Acid | September 2020 | May 2023 | Abandon | 32 | 2 | 1 | No | No |
| 17002169 | Method for the Stimulation of Human Immune Cells | August 2020 | October 2022 | Allow | 25 | 1 | 1 | No | No |
| 17001440 | ANTI-MICROBIAL AMALGAMATE OF NON-TOXIC NATIVE COMPOSITION | August 2020 | April 2024 | Abandon | 43 | 3 | 1 | No | No |
| 16986469 | EXTRACTS OF HALIMIONE PORTULACOIDES AND THEIR APPLICATION | August 2020 | August 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16983975 | HONEY-BASED GEL COMPOSITION | August 2020 | March 2024 | Abandon | 43 | 2 | 0 | No | No |
| 16965754 | COMPOSITION FOR PREVENTING OR TREATING DRY EYE SYNDROME, CONTAINING AUCUBA JAPONICA EXTRACT | July 2020 | November 2023 | Allow | 40 | 3 | 1 | Yes | No |
| 16946721 | THERAPEUTIC HERBAL COMPOSITIONS FOR IMPROVING JOINT HEALTH | July 2020 | March 2022 | Allow | 21 | 3 | 1 | Yes | No |
| 16911716 | PROCESS FOR PRODUCING AN EXTRACT CONTAINING TETRAHYDROCANNABINOL AND CANNABIDIOL FROM CANNABIS PLANT MATERIAL, AND CANNABIS EXTRACTS | June 2020 | June 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16906844 | COMPOSITION FOR ALLEVIATING SKIN INFLAMMATION CAUSED BY YELLOW DUST AND FINE PARTICULATE, COMPRISING NATURAL PLANT EXTRACT | June 2020 | August 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16898472 | Nutraceuticals for Reducing Myeloid Suppressor Cells | June 2020 | March 2023 | Abandon | 33 | 2 | 0 | No | No |
| 16897378 | COMPOSITION FOR RELIEVING STRESS AND ENHANCING IMMUNITY AND PREPARATION METHOD THEREOF | June 2020 | December 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16858254 | THERAPEUTIC COMPOSITION INCLUDING CARBONATED SOLUTION | April 2020 | September 2023 | Allow | 40 | 4 | 0 | No | No |
| 16856241 | COMPOSITIONS OF MARINE BOTANICALS TO PROVIDE NUTRITION TO AGING AND ENVIRONMENTALLY DAMAGED SKIN | April 2020 | April 2022 | Allow | 23 | 1 | 0 | No | No |
| 16854349 | OLIVE COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | April 2020 | February 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16851637 | METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS | April 2020 | January 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16834351 | ADMINISTERING COMPOSITIONS FOR IMPROVED IMMUNE SYSTEM FUNCTIONING | March 2020 | January 2022 | Allow | 22 | 1 | 0 | No | No |
| 16873368 | RaeLinn - JKL | March 2020 | November 2021 | Abandon | 19 | 1 | 0 | No | No |
| 16821421 | THERAPEUTIC COMPOSITION INCLUDING CARBONATED SOLUTION | March 2020 | August 2023 | Allow | 41 | 3 | 1 | No | No |
| 16816214 | COMPOSITIONS AND METHODS FOR TREATMENT OF ALCOHOL INDUCED LIVER INJURY | March 2020 | November 2022 | Abandon | 32 | 1 | 1 | No | No |
| 16806000 | MATERIALS AND METHODS FOR IMPROVING IMMUNE RESPONSES AND SKIN AND/OR MUCOSAL BARRIER FUNCTIONS | March 2020 | September 2022 | Allow | 30 | 1 | 1 | No | No |
| 16726323 | SOYBEAN SEED EXTRACT, METHOD FOR PRODUCING THE SAME AND USES THEREOF | December 2019 | February 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16725246 | SOYBEAN SEED EXTRACT, METHOD FOR PRODUCING THE SAME AND USES THEREOF | December 2019 | February 2022 | Allow | 26 | 1 | 0 | No | No |
| 16725608 | COMPOSITION, CONTAINING QUISQUALIS INDICA EXTRACT, FOR PREVENTING OR TREATING PROSTATIC HYPERPLASIA | December 2019 | June 2023 | Allow | 41 | 3 | 0 | No | No |
| 16725125 | SOYBEAN SEED EXTRACT, METHOD FOR PRODUCING THE SAME AND USES THEREOF | December 2019 | August 2022 | Allow | 31 | 2 | 0 | No | No |
| 16722292 | SOYBEAN SEED EXTRACT, METHOD FOR PRODUCING THE SAME AND USES THEREOF | December 2019 | May 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16610859 | METHODS OF TREATING SYSTEMIC GRAFT-VERSUS-HOST DISEASE WITH EXTRACELLULAR VESICLES | November 2019 | August 2022 | Allow | 33 | 2 | 1 | No | No |
| 16659591 | SEASONED LAVER INCLUDING HEMP OIL AND MANUFACTURING METHOD THEREOF | October 2019 | November 2021 | Abandon | 25 | 0 | 1 | No | No |
| 16653647 | METHODS AND COMPOSITIONS FOR TREATING JOINT DISEASE | October 2019 | January 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16550066 | EDIBLE CRICKET COMPOSITION FOR PREVENTING HAIR LOSS, IMPROVING HAIR FOLLICLE, AND PROMOTING HAIR REGROWTH | August 2019 | January 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16516622 | PLANT EXTRACT CONTAINING DIKETOPIPERAZINE AND METHOD FOR PRODUCING SAME | July 2019 | April 2022 | Allow | 33 | 1 | 1 | No | No |
| 16507838 | Protective Effects of Oil Palm Composition on Alzheimer's Disease | July 2019 | February 2022 | Abandon | 31 | 3 | 0 | No | No |
| 16436581 | Method of Making a Dietary Supplement | June 2019 | February 2022 | Abandon | 32 | 2 | 0 | No | No |
| 16433169 | ORAL ADMINISTRATION OF MELANIN FOR PROTECTION AGAINST RADIATION | June 2019 | February 2021 | Allow | 21 | 1 | 0 | No | No |
| 16465984 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | May 2019 | September 2021 | Allow | 27 | 1 | 1 | Yes | No |
| 16461786 | NOVEL FORMULATIONS AND USES THEREFOR | May 2019 | March 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16407827 | Oat Fractions With Enhanced Avenanthramide Concentration and Methods of Making | May 2019 | December 2021 | Allow | 32 | 2 | 1 | Yes | Yes |
| 16345401 | INHIBITOR FOR COGNITIVE FUNCTION DECLINE | April 2019 | April 2021 | Allow | 24 | 1 | 0 | No | No |
| 16392830 | EXCIPIENT SYSTEM FOR TOPICAL DELIVERY OF PHARMACEUTICAL AGENTS | April 2019 | January 2022 | Abandon | 32 | 2 | 1 | No | No |
| 16289198 | PORE MINIMIZER | February 2019 | February 2021 | Allow | 24 | 1 | 0 | No | No |
| 16246411 | ENCAPSULATED CANNABINOID FORMULATIONS FOR TRANSDERMAL DELIVERY | January 2019 | March 2020 | Allow | 14 | 1 | 1 | No | No |
| 16246400 | ENCAPSULATED CANNABINOID FORMULATIONS FOR ORAL DELIVERY | January 2019 | March 2020 | Allow | 14 | 1 | 1 | No | No |
| 16244719 | NOOTROPIC AND SKIN SUPPLEMENT COMPOSITIONS AND METHOD TO PROVIDE A TAILORED SUPPLEMENT | January 2019 | May 2022 | Abandon | 40 | 2 | 1 | No | No |
| 16221167 | Cream and Oil for Facial Rejuvenation | December 2018 | December 2020 | Allow | 24 | 0 | 1 | No | No |
| 16210267 | WATER-SOLUBLE CANNABINOIDS AND METHODS OF MAKING SAME | December 2018 | December 2021 | Allow | 37 | 2 | 1 | No | No |
| 16200344 | ANTI-CANCER DRUG COMPOSITION INCLUDING GANODERMA EXTRACT AND AMPHOTERICIN B | November 2018 | June 2021 | Abandon | 31 | 1 | 1 | No | No |
| 16099860 | HOP PROCESSED PRODUCT | November 2018 | August 2022 | Abandon | 45 | 3 | 1 | Yes | No |
| 16183022 | SOLID AGAVE SYRUP COMPOSITIONS | November 2018 | April 2021 | Allow | 29 | 1 | 0 | No | No |
| 16178850 | SIMMONDSIN FORMULATION | November 2018 | March 2022 | Allow | 41 | 2 | 1 | No | No |
| 16171297 | COMPOSITIONS AND METHODS OF BDNF ACTIVATION | October 2018 | August 2022 | Allow | 46 | 3 | 2 | Yes | No |
| 16095447 | PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD COMPRISING OAT EXTRACT AVENANTHRAMIDE C OR DERIVATIVE THEREOF AS EFFECTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE | October 2018 | August 2021 | Allow | 34 | 1 | 1 | Yes | No |
| 16158399 | USES OF MENTHA ESSENTIAL OIL | October 2018 | September 2021 | Abandon | 36 | 2 | 1 | No | No |
| 16092374 | USE OF CANNABIDIVARIN IN THE TREATMENT OF AUTISM SPECTRUM DISORDER, ASSOCIATED DISORDERS AND SCHIZOPHRENIA | October 2018 | April 2023 | Allow | 54 | 3 | 1 | No | Yes |
| 16133760 | METHOD FOR PREPARING TEA LEAF EXTRACT | September 2018 | March 2021 | Allow | 30 | 1 | 1 | No | No |
| 16133033 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS COMPRISING OAT EXTRACT AS AN ACTIVE INGREDIENT | September 2018 | April 2021 | Allow | 31 | 1 | 1 | No | No |
| 16111527 | Method of Using Composition Containing Hovenia Dulcis Thunb. Extract as Active Ingredient for Prevention and Treatment of Bone Diseases | August 2018 | September 2021 | Allow | 36 | 2 | 1 | No | No |
| 16110371 | COMPOSITION FOR PROTECTING CELL FROM OXIDATIVE STRESS COMPRISING GREEN TEA EXTRACT WHICH HAS MODIFIED AMOUNTS OF INGREDIENTS | August 2018 | May 2021 | Allow | 33 | 2 | 1 | No | No |
| 16105511 | COMPOSITION FOR TREATMENT OR PREVENTION OF LUNG CANCER AND A METHOD THEREFORE | August 2018 | August 2022 | Abandon | 48 | 4 | 0 | No | No |
| 16100956 | METHOD FOR CELL REJUVENATION USING ROSA ROXBURGHII FRUIT EXTRACTS | August 2018 | February 2022 | Abandon | 42 | 4 | 0 | No | No |
| 15998364 | Acid-relief agent and method of preparation | August 2018 | January 2021 | Abandon | 29 | 1 | 1 | No | No |
| 16058484 | TRADITIONAL CHINESE MEDICINE COMPOSITION AND USE THEREOF | August 2018 | February 2021 | Allow | 30 | 1 | 1 | No | No |
| 16059002 | METHOD FOR REDUCTION, SUPPRESSION, OR ELIMINATION OF ANXIETY OR MARIJUANA/CANNABIS EFFECTS AND RELATED MARIJUANA/CANNABIS PRODUCT BY PROCESS | August 2018 | March 2023 | Abandon | 55 | 4 | 1 | No | No |
| 16076092 | INHIBITOR OF INFLAMMASOME ACTIVATION | August 2018 | February 2022 | Allow | 43 | 3 | 1 | Yes | No |
| 16075795 | Composition of Plant Extracts That Increase D�derlein's Bacilli, Used for the Treatment of Sexually Transmitted Diseases (STD) and the Human Papillomavirus (HPV), Having an Aphrodisiac Effect | August 2018 | January 2021 | Abandon | 29 | 1 | 0 | No | No |
| 16073813 | NICOTINE FREE HERBAL COMPOSITION FOR SMOKING DE-ADDICTION AND TREATMENT OF SIDE-EFFECTS AND/OR AILMENTS FROM SMOKING | July 2018 | March 2021 | Allow | 31 | 2 | 0 | Yes | No |
| 16048023 | CANNABINOID COMPOSITION HAVING AN OPTIMIZED FATTY ACID EXCIPIENT PROFILE | July 2018 | December 2021 | Abandon | 41 | 2 | 1 | No | No |
| 16070899 | COMPOSITE LIQUID PHARMACEUTICAL COMPOSITION COMPRISING CRUDE DRUG-STABILIZING DRIED POWDER | July 2018 | August 2021 | Abandon | 37 | 2 | 1 | No | No |
| 16037836 | COMPOSITION FOR TREATING DIABETIC DISEASE | July 2018 | January 2022 | Abandon | 42 | 3 | 0 | No | No |
| 16070391 | BIOACTIVE COMPOSITIONS FROM GINSENG PLANT (PANAX SPP.) AND METHODS FOR THEIR PRODUCTION AND USE | July 2018 | June 2021 | Allow | 35 | 2 | 1 | No | No |
| 16070006 | FORMULATION FOR TREATING MIGRAINE | July 2018 | January 2021 | Abandon | 31 | 1 | 1 | No | No |
| 16069265 | ACTIVE INGREDIENT OBTAINED FROM OPHIOPOGON JAPONICUS FOR THE TREATMENT OF ATOPIC DERMATITIS | July 2018 | December 2021 | Allow | 41 | 3 | 1 | No | No |
| 16030462 | POWDER FORMULATION HAVING HYPOGLYCEMIC AND HYPOLIPIDEMIC FUNCTIONS AND METHOD FOR PREPARING THE SAME | July 2018 | November 2020 | Allow | 29 | 1 | 1 | No | No |
| 16068769 | STABLE PALM INFLORESCENCE SAP POWDER COMPOSITIONS AND ITS PHARMACOLOGICAL EFFECTS | July 2018 | July 2021 | Allow | 36 | 1 | 1 | No | No |
| 16068535 | BICONTINUOUS MICROEMULSIONS AND METHODS OF USE THEREOF | July 2018 | February 2022 | Abandon | 43 | 3 | 1 | No | No |
| 16068408 | Agent for Activating Astrocyte Glucose Metabolism | July 2018 | December 2020 | Allow | 29 | 1 | 1 | No | No |
| 16068213 | FOOD COMPOSITION FOR PREVENTING AND ALLEVIATING FEMALE MENOPAUSE SYMPTOMS CONTAINING GRAPE SEED EXTRACT, VALERIAN EXTRACT AND SAFFLOWER SEED EXTRACT | July 2018 | August 2020 | Abandon | 25 | 0 | 1 | No | No |
| 16023327 | BOYSENBERRY COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF | June 2018 | July 2023 | Abandon | 60 | 5 | 1 | No | No |
| 16067376 | PROCESS FOR PREPARING A CRASSOCEPHALUM CREPIDIOIDES EXTRACT, EXTRACT PREPARED THEREBY AND USE OF THE EXTRACT | June 2018 | January 2021 | Allow | 31 | 2 | 0 | No | No |
| 16065447 | SKIN CLEANSING COMPOSITION | June 2018 | November 2020 | Allow | 29 | 1 | 1 | No | No |
| 16010816 | SKIN MASSAGE GEL AND METHOD OF PREPARING THE SAME | June 2018 | February 2020 | Allow | 20 | 1 | 1 | No | No |
| 16010719 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING A URINARY TRACT INFECTION | June 2018 | January 2021 | Abandon | 30 | 1 | 1 | No | No |
| 16010226 | COMPOSITION CONTAINING MELDONIUM DIHYDRATE FOR THE PREVENTION AND TREATMENT OF NEURODEGNERATIVE DISEASES | June 2018 | December 2021 | Abandon | 42 | 1 | 1 | No | No |
| 16007143 | Cosmetic Compositions and Methods for Their Use in Firming Skin | June 2018 | March 2022 | Allow | 45 | 4 | 1 | Yes | Yes |
| 16007524 | COMPOSITIONS AND METHODS FOR ENHANCING HYPERTHERMIA THERAPY | June 2018 | July 2020 | Allow | 25 | 3 | 0 | No | No |
| 16003875 | TOPICAL SKINCARE COMPOSITIONS COMPRISING CENTELLA ASIATICA SELECTED TRITERPENES | June 2018 | December 2020 | Allow | 30 | 2 | 1 | No | No |
| 16060386 | TOPICAL SKIN CARE COMPOSITIONS COMPRISING MYRSINE AFRICANA EXTRACTS | June 2018 | August 2021 | Abandon | 38 | 2 | 1 | No | No |
| 15995128 | USE OF FLAXSEED AND FLAXSEED DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISORDERS AND VIRAL DISEASES | June 2018 | April 2021 | Abandon | 34 | 1 | 2 | No | No |
| 15994554 | COMPOSITIONS AND METHODS FOR TREATING VARICOSE VEINS | May 2018 | April 2022 | Abandon | 46 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WINSTON, RANDALL O.
With a 22.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 38.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner WINSTON, RANDALL O works in Art Unit 1655 and has examined 781 patent applications in our dataset. With an allowance rate of 55.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner WINSTON, RANDALL O's allowance rate of 55.3% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WINSTON, RANDALL O receive 1.81 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by WINSTON, RANDALL O is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +38.7% benefit to allowance rate for applications examined by WINSTON, RANDALL O. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.5% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 30.2% of cases where such amendments are filed. This entry rate is in the 45% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 144.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 89% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 83.9% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 68.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.6% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 57% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.